Hyperthermia with GEM/CIS & Gemzar Alone in Tx of Pancreatic Cancer

Hi, everyone
Although below copied message is related to pancreatic solid tumors but as you know,it may be of benefit to CCA too. So take a look .The company BSDM makes RFA and microwave radiation equipments;see bottom message for a simple introduction.

SALT LAKE CITY, Feb 21, 2012 (BUSINESS WIRE) — BSD Medical Corporation BSDM – reports initiation of a randomized, multicenter, Phase III clinical study using the BSD-2000 Hyperthermia System to deliver hyperthermia in combination with chemotherapy for the treatment of pancreatic cancer patients. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine plus cisplatin) to chemotherapy (gemcitabine) alone. Patients will be randomized following standard surgical resection of the tumor. The coordinating investigator is Rolf D. Issels, MD PhD, Department of Medical Oncology, Klinikum Grosshadern, Munich University Medical School, Munich, Germany.

The researchers had previously reported data from a Phase II study that utilized chemotherapy and hyperthermia, delivered using the BSD-2000 Hyperthermia System, to treat 21 inoperable pancreatic cancer patients who were resistant to or had failed previous chemotherapy gemcitabine treatments, a patient population with a dire prognosis. The study results demonstrated a low toxicity rate and an overall survival of 16.9 months. By comparison, the median survival for inoperable pancreatic cancer patients after gemcitabine treatment is only 6 months.

The study is scheduled to open for patient enrollment April 1, 2012. The following clinical sites will initially participate in the clinical study: Klinikum Grosshadern of Ludwigs-Maximilans-Universitat Munchen, Klinik Bad Trissl Oberaudorf, Rotkreuzkrankenhaus Munchen, Universitatsklinikum Dusseldorf, and Universitatsklinikum Tubingen. These sites all utilize the BSD-2000 Hyperthermia System.

About the company:
About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue.